3 ms·
I just read this NYer article in its entirety. It's brilliant. As a CS-AI guy and biologist working in pharma (and on the margins of cancer), I found the arti
by randcraw 9y ago
I just read this NYer article in its entirety. It's brilliant.
As a CS-AI guy and biologist working in pharma (and on the margins of cancer), I found the article's thesis fascinating as a great look into the complexity of mining available bio data and as well as the limits inherent in mining only the signals that already exist.
It's clear now that between the immune system and the body's gene activation networks that regulate each person's biological "soil", we need to 1) look well beyond the cancer itself to how each of us responds to the arrival of cancer cells as well as 2) how therapists can judge the actual risk from cancer, and 3) how we help the immune system to kick cancer's ass.
After reading this piece, I finally bought both of Mukherjee's bestseller books. I already know a fair bit about both topics (cancer, genes), but it's now clear to me that the author's ability to focus my attention on the crux message while telling a great story makes the investment of my time in reading him easily worth the occasional revisit of material I already know.
- hackeraccount 9y agoMukherjee is like candy for me. I have no idea what it is but either his style or methodology just sucks me in.
- jzl 9y agoI've read The Emperor of All Maladies. Overall I liked it a lot, but there are several long stretches with exceptionally boring material about the politics of competing philanthropic groups and things of that nature. While the fundraising side of cancer research is an important topic he spends far too much time on it. And he intersperses with contemporary "patient stories" from his practice that felt more like filler than relevant material. The book did not need to be 600 pages. That said the good parts are really good and it's worth putting up with the rest for them.